FDA OKs first drug made to reduce excessive sweating

June 29, 2018 by Linda A. Johnson
FDA OKs first drug made to reduce excessive sweating
This undated image provided by Dermira Inc. shows the drug Qbrexz. The U.S. Food and Drug Administration approved Qbrexza, the first drug developed to reduce excessive sweating, a common condition that can cause anxiety. Maker Dermira Inc. said Friday, June 29, 2018, that its drug was approved for excessive underarm sweating. (Dermira Inc. via AP)

U.S. regulators on Friday approved the first drug developed specifically to reduce excessive sweating, a common condition that can cause people anxiety and affect their social lives.

The Food and Drug Administration approved Qbrexza for excessive underarm sweating and will be available in October. The drug is inside a cloth wiped over the skin daily to block sweat glands from activating.

Its manufacturer, Dermira Inc., refused to disclose the price, as drugmakers normally do.

An estimated 15.3 million Americans have some form of excessive sweating, but only 1 in 4 get treatment. Current treatment options include Botox injections, surgery to remove sweat glands, procedures using lasers and other devices, and drugs approved for other conditions that block the body's chemical messengers to reduce sweat production throughout the body.

Side effects of Qbrexza include blurred vision, constipation, burning and itchy skin, head and throat pain, and dry mouth, eyes and skin.

Dermira said in one study, 53 percent of patients reported Qbrexza reduced sweat production by roughly half, versus 28 percent in a comparison group using a nonmedicated cloth.

Explore further: FDA approves first generic under-the-tongue suboxone

Related Stories

FDA approves first generic under-the-tongue suboxone

June 18, 2018
(HealthDay)—The first generic version of an under-the-tongue film to treat opioid addiction has been approved by the U.S. Food and Drug Administration.

For some, too much sweat takes emotional toll

April 6, 2017
(HealthDay)—Don't sweat the small stuff. That's sound advice for most—but not if you're one of the 7 million Americans diagnosed with hyperhidrosis.

FDA approves Botox for migraine headaches

October 15, 2010
(AP) -- Federal health officials approved the wrinkle-smoothing injection Botox for migraine headaches on Friday, giving drugmaker Allergan clearance to begin marketing its drug to patients with a serious history of the ...

Botox now used for urinary incontinence

March 14, 2012
When you think of Botox injections, you probably think of getting rid of unwanted wrinkles around the eyes or forehead, but recently the U.S. Food and Drug Administration (FDA) approved using the injections to help patients ...

Scientists unravel the mystery of a rare sweating disorder

October 20, 2014
An international research team discovered that mutation of a single gene blocks sweat production, a dangerous condition due to an increased risk of hyperthermia, also known as heatstroke. The gene, ITPR2, controls a basic ...

First drug approved for most common inherited kidney disease

April 24, 2018
The U.S. Food and Drug Administration has approved the first drug to slow kidney decline in patients with the most common inherited kidney disease.

Recommended for you

Novel botulinum toxin compound relieves chronic pain

July 18, 2018
A modified form of botulinum toxin gives long-lasting pain relief in mice without adverse effects and, in time, could replace opioid drugs as a safe and effective way of treating chronic pain, according to research by UCL, ...

FDA recalls heart medication valsartan, citing cancer concerns

July 17, 2018
The U.S. Food and Drug Administration issued a voluntary recall of several medications that contain the active ingredient valsartan, which is used to treat high blood pressure and heart failure.

Opioids given too easily to children: study

July 16, 2018
(HealthDay)—Many children are prescribed powerful opioid painkillers they don't really need, putting them and those around them at risk, a new study shows.

Study reveals opioid patients face multiple barriers to treatment

July 12, 2018
In areas of the country disproportionately affected by the opioid crisis, treatment programs are less likely to accept patients paying through insurance of any type or accept pregnant women, a new Vanderbilt study found.

Report details possible conflict of interest issues for FDA advisors

July 6, 2018
Charles Piller, a contributing correspondent for the journal Science, has published a Feature piece in the journal detailing what he describes as possible conflicts of interest issues by people who serve as advisors to the ...

Opioid epidemic responses overlook gender

July 5, 2018
Yale health experts warn that current efforts to confront the growth of opioid addiction and overdose deaths must better incorporate an understanding of how women fit into this epidemic.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.